Norman Gordon, MD
Neurology · East Providence, RINPI 1467481648
Payments from drug & device makers
Across 1,820 payments — averaging $115.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$43K
- Teva Pharmaceuticals USA, Inc.$35K
- AbbVie$31K
- Biohaven Pharmaceuticals, Inc.$13K
- EMD Serono, Inc.$11K
- Neurelis, Inc.$11K
- plus $66K from 54 others
Across 6 payments — averaging $2916.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$18K
What the payments were for
- Consulting fees$17,7839%
- Speaking & faculty fees$145,12970%
- Travel & lodging$3,9752%
- Food & beverage$39,02819%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$41,171
- AJOVY$33,024
- UBRELVY$27,633
- NURTEC ODT$25,316
- VALTOCO$10,328
- INBRIJA$8,280
- Mavenclad$6,518
- NORTHERA$5,155
- APOKYN$2,122
- RYTARY$1,900
- Leqembi$1,760
- Bafiertam$1,027
- KYNMOBI$934
- Vumerity$361
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$273
- Fycompa$221
- PERCEPT PC BRAINSENSE$181
- TYSABRI$150
- VYEPTI$137
- Exablate$134
How this compares
$210,164 in reported general payments places this provider in the 90th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 31 | $269,329 |
| NuplazidPimavanserin Tartrate | 38 | $244,750 |
| IngrezzaValbenazine Tosylate | 26 | $216,793 |
| ImitrexSumatriptan Succinate | 13 | $135,850 |
| Aimovig AutoinjectorErenumab-Aooe | 164 | $120,884 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $109,923 |
| MayzentSiponimod | 11 | $98,633 |
| FingolimodFingolimod Hcl | 12 | $86,614 |
| GocovriAmantadine Hcl | 13 | $75,488 |
| FycompaPerampanel | 61 | $73,221 |
| Nurtec OdtRimegepant Sulfate | 45 | $69,325 |
| QuliptaAtogepant | 57 | $67,980 |
| RytaryCarbidopa/Levodopa | 121 | $63,241 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $48,622 |
| BotoxOnabotulinumtoxina | 25 | $30,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Avonex (4 Pack) | $1,770 | $379,25244 claims |
| Acadia Pharmaceuticals IncNuplazid | $5,387 | $244,75038 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $647 | $216,79326 claims |
| AbbVieQulipta, Botox, Ubrelvy | $31,385 | $127,027106 claims |
| NovartisMayzent | $1,764 | $98,63311 claims |
| MDD US Operations, LLCGocovri | $3,137 | $75,48813 claims |
| Eisai Inc.Fycompa | $5,148 | $73,22161 claims |
| PfizerNurtec Odt | $9,499 | $69,32545 claims |
| Amneal Pharmaceuticals LLCRytary | $3,708 | $63,241121 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $512 | $48,62225 claims |
| SK Life Science, Inc.Xcopri | $1,612 | $21,28119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 86 neurology providers in Rhode Island.
Other neurology in East Providence
- Preeti GuptaEast Providence$8K
- Stephen SallowayProvidence$16.1M
- Brian OttProvidence$4.1M
- Jonathan DrakeProvidence$3M
- Chuang WuProvidence$1.2M
- Peter BellafioreWakefield$274K
- Syed RizviProvidence$170K
- Albert MaranoJohnston$145K
- Jonathan CahillProvidence$142K
- John EastonProvidence$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.